Export 7 results:
Author Title [ Type(Desc)] Year
Filters: Author is Graham, B S  [Clear All Filters]
Journal Article
B. S. Graham, McElrath, M. J., Connor, R. I., Schwartz, D. H., Gorse, G. J., Keefer, M. C., Mulligan, M. J., Matthews, T. J., Wolinsky, S. M., Montefiori, D. C., Vermund, S. H., Lambert, J. S., Corey, L., Belshe, R. B., Dolin, R., Wright, P. F., Korber, B. T., Wolff, M. C., and Fast, P. E., Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group., J Infect Dis, vol. 177, no. 2, pp. 310-9, 1998.
T. G. Evans, Keefer, M. C., Weinhold, K. J., Wolff, M., Montefiori, D., Gorse, G. J., Graham, B. S., McElrath, M. J., Clements-Mann, M. L., Mulligan, M. J., Fast, P., Walker, M. C., Excler, J. L., Duliege, A. M., and Tartaglia, J., A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers., J Infect Dis, vol. 180, no. 2, pp. 290-8, 1999.
M. L. Clements-Mann, Weinhold, K., Matthews, T. J., Graham, B. S., Gorse, G. J., Keefer, M. C., McElrath, M. J., Hsieh, R. H., Mestecky, J., Zolla-Pazner, S., Mascola, J., Schwartz, D., Siliciano, R., Corey, L., Wright, P. F., Belshe, R., Dolin, R., Jackson, S., Xu, S., Fast, P., Walker, M. C., Stablein, D., Excler, J. L., Tartaglia, J., and Paoletti, E., Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group., J Infect Dis, vol. 177, no. 5, pp. 1230-46, 1998.
M. J. McElrath, Corey, L., Montefiori, D., Wolff, M., Schwartz, D., Keefer, M., Belshe, R., Graham, B. S., Matthews, T., Wright, P., Gorse, G., Dolin, R., Berman, P., Francis, D., Duliege, A. M., Bolognesi, D., Stablein, D., Ketter, N., and Fast, P., A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation Group., AIDS Res Hum Retroviruses, vol. 16, no. 9, pp. 907-19, 2000.
J. E. Ledgerwood, Costner, P., Desai, N., Holman, L., Enama, M. E., Yamshchikov, G., Mulangu, S., Hu, Z., Andrews, C. A., Sheets, R. A., Koup, R. A., Roederer, M., Bailer, R., Mascola, J. R., Pau, M. G., Sullivan, N. J., Goudsmit, J., Nabel, G. J., and Graham, B. S., A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults., Vaccine, vol. 29, no. 2, pp. 304-13, 2010.
B. S. Graham, Keefer, M. C., McElrath, M. J., Gorse, G. J., Schwartz, D. H., Weinhold, K., Matthews, T. J., Esterlitz, J. R., Sinangil, F., and Fast, P. E., Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group., Ann Intern Med, vol. 125, no. 4, pp. 270-9, 1996.
M. C. Keefer, Wolff, M., Gorse, G. J., Graham, B. S., Corey, L., Clements-Mann, M. L., Verani-Ketter, N., Erb, S., Smith, C. M., Belshe, R. B., Wagner, L. J., McElrath, M. J., Schwartz, D. H., and Fast, P., Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group., AIDS Res Hum Retroviruses, vol. 13, no. 14, pp. 1163-77, 1997.